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LETTERS
30%–50% of immunosuppressed 
patients with coccidioidomycosis (3). 
Disseminated coccidioidomycosis 
typically involves the skin, meninges, 
or bone (3); however, intraocular 
involvement has also been described 
(1). A review of the literature shows 
25 reported cases of intraocular 
coccidioidomycosis. When present, 
intraocular involvement is associated 
with serious consequences, frequently 
leading to eye enucleation; 1 case 
series described eventual enucleation 
in 50% of reported patients who 
did not die from disseminated 
coccidioidal infection (2). 
For the patient in our report, 
in the setting of reported trauma 
and negative metastatic work-up 
results, it is unclear whether ocular 
disease resulted independently 
as an exogenous infection or 
from endogenous lymphatic and/
or hematogenous spread from 
the patient’s lung. Diagnosis of 
coccidioidal endophthalmitis can 
be diffi cult, often relying on serum 
or nonocular tissue evaluation (4). 
Intraocular coccidioidal involvement 
usually occurs with widespread 
infection (5). Thus, even with 
apparent isolated ocular fi ndings, 
evaluation for disseminated disease is 
warranted, including a careful history 
and physical examination, CT chest 
scan, bone scan, intracranial imaging, 
and lumbar puncture. Evaluation for 
immunosuppression, including HIV 
status, is warranted.
The optimal systemic antifungal 
therapy for intraocular coccidioidal 
infection is unclear, although 
fl uconazole is the drug of choice for 
extrapulmonary coccidioidomycosis, 
including meningitis (3). Fluconazole 
has good ocular penetration; however, 
voriconazole also achieves excellent 
intraocular levels (6) at lower 90% 
minimum inhibitory concentration 
levels (7). Furthermore, Gabrielian 
and Hariprasad (8) described an 
immunocompetent patient with 
treated and stable nonocular 
disseminated coccidioidomycosis 
who showed development of new 
vitritis and choroiditis 8 weeks 
into high-dose fl uconazole therapy; 
his intraocular disease resolved 
within 2–4 weeks of transition to 
voriconazole. 
The patient in our report received 
systemic voriconazole for 4 weeks 
plus repeated intravitreal voriconazole 
injections on follow-up. It is possible 
that this initial therapy had an effect 
on his positive outcome and the 
avoidance of eye enucleation. The 
optimal length of therapy is unclear; 
however, this patient will receive 
prolonged treatment (>1 year) with 
high-dose fl uconazole, followed by 
a slow taper guided by serologic 
testing and regular ophthalmologic 
examination. Future research should 
evaluate which antifungal therapy is 
superior and the appropriate duration 
of treatment.
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Human MRSA 
Isolates with Novel 
Genetic Homolog, 
Germany
To the Editor: Methicillin-
resistant Staphylococcus aureus 
(MRSA) represents a major cause 
of hospital-, community- and 
livestock-acquired infections that 
are increasingly diffi cult to manage 
(1–3). Detection and identifi cation 
of MRSA by culture and nucleic 
acid–based methods is challenged 
by heterogeneous penicillin-binding 
protein 2a (PBP2a) expression and 
variability of the staphylococcal 
cassette chromosome (SCCmec) 
elements. Recently, a new SCCmec 
element (XI) carried in bovine and 
human isolates was described (4,5). 
This SCCmec element contains a 
novel mecA homolog, designated 
mecALGA251, that is not detectable by 
usual mecA-specifi c PCR approaches 
and PBP2a agglutination tests. 
García-Álvarez et al. reported this 
novel mecA homolog exhibited 70% 
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identity at DNA level to the mecA 
gene, and suggested these strains were 
transmitted from livestock to humans 
(4).
To search for isolates possessing 
the novel mecALAG251, we screened 
S. aureus databases for those entries 
describing oxacillin/cefoxitin-resistant 
phenotypes that were negative for 
mecA by PCR (6) or harbored S. aureus 
protein A gene (spa) types known to 
be associated with the occurrence of 
mecALGA251 (4,5). The databases of the 
University Hospital Münster contain 
S. aureus spa typing results of S. 
aureus isolates obtained from hospital 
admission screenings and specimens 
from patients treated at University 
Hospital Münster. Moreover, they 
include isolates derived from human 
and animal subjects, respectively, of 
2 cross-border projects between the 
Netherlands and Germany: MRSA-net 
EUREGIO Twente/Münsterland and 
SafeGuard MRSA vet-net (2,7). 
The presence of mecALGA251 was 
verifi ed by using a specifi c PCR that 
applied newly designed primers: 
mecAL1 (5′-AGC TGG CCA TCC 
CTT TAT TT-3′) and mecAL2 (5′-
CTG GCA TAT GGA GAA GAA 
GAA A-3′), derived from the sequence 
of S. aureus LGA251 provided by 
M. Holden (Wellcome Trust Sanger 
Institute, Hinxton, UK; accession 
no. FR821779). The sensitivities and 
specifi cities of primers were checked 
by applying S. aureus and other 
staphylococcal isolates of different 
clonal backgrounds (8,9). Positive 
PCR products were sequenced to 
confi rm identifi cation of mecALGA251; 
the isolates were then characterized by 
typing the SCCmec region with specifi c 
primers for mecR1, mecI, blaZ, ccrA, 
and ccrB related to type XI SCCmec 
as described by García-Álvarez et al. 
(4). Identifi ed isolates were tested for 
PBP2a by using a latex agglutination 
assay (Oxoid Deutschland GmbH, 
Wesel, Germany). We used Etest 
(bioMérieux SA, Marcy-l’Étoile, 
France) for antibacterial agent 
susceptibility testing of β-lactams and 
other antibacterial agents. 
We report on 16 (clinically derived, 
n = 14; ovine origin, n = 2) oxacillin/
cefoxitin-resistant S. aureus isolates 
possessing the recently described 
mecALGA251 isolate, but lacking the 
classical mecA gene currently defi ning 
classic MRSA (Table). The isolates 
belong to spa types t843, t978, t1535, 
t1773, and t7189. Concurring with the 
fi ndings in the United Kingdom and 
Denmark, we found t843 to be the 
most prevalent spa type. Results of the 
PBP2a latex agglutination assay were 
negative for all isolates except for 1 
(no. 14), which was indeterminable. 
García-Álvarez et al. described 
negative results for all tested isolates 
(4); Shore et al. reported inconsistent 
results with this test (5).
According to the Clinical and 
Laboratory Standards Institute 
MIC interpretative standards for 
staphylococci (10), antibacterial 
agent susceptibility testing revealed 
resistance to benzylpenicillin and 
oxacillin/cefoxitin for all isolates. 
All isolates were shown to produce 
β-lactamases. Apart from the general 
categorization of oxacillin/cefoxitin-
resistant isolates as resistant to all 
β-lactams, the MICs of drugs for 
all isolates included were read as 
susceptible for imipenem (MIC for 
90% of strains tested 0.5 μg/mL) as well 
as for the anti-MRSA cephalosporin 
ceftobiprole (MIC for 90% of strains 
tested 1 μg/mL applying provisional 
breakpoint <4 μg/mL). A large range 
of MICs were observed for classic 
cephalosporins, ranging from those 
isolates categorized as susceptible 
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Table. Description of mecALGA251-positive isolates regarding their spa type, ability to grow on selective MRSA media, PBP2a 





isolation Specimen spa type






Human         
 1 2010 Nasal swab t843 + – – + +
 2 2010 Wound t843 + – – + +
 3 2010 Wound t843 + – – + +
 4 2010 Nasal swab t843 + – – + +
 5 2011 Nasal swab t843 + – – + +
 6 2004 Sputum t843 + – – + +
 7 2010 Nasal swab t843 + – – + +
 8 2007 Mouth swab t843 + – – + +
 9 2010 Nasal swab t843 + – – + +
 10 2011 Nasal swab t843 + – – + +
 11 2011 Joint aspirate t843 + – – + +
 12 2007 Nasal swab t978 + – – + +
 13 2010 Nasal swab t7189 + – – + +
 14 2009 Nasal swab t1773 + ND – + +
Sheep      –   
 15 2010 Unknown t1535 + – – + +
 16 2010 Unknown t1535 + – – + +
*spa, Staphylococcus aureus protein A; MRSA, methicillin-resistant S. aureus; PBP2a, penicillin-binding protein 2a; SCC, staphylococcal cassette 
chromosome; +, positive; –, negative; ND, not done. 
†ChromID MRSA-Plates (bioMérieux, Marcy-l'Étoile, France). 
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(cephalothin, n = 15; cefuroxime, n = 
10; ceftriaxone, n = 2; cefepime, n = 9) 
to those classifi ed as resistant.
We observed relatively low 
oxacillin/cefoxitin MICs for some 
of the mecALAG251-positive isolates 
(MIC 3 μg/mL, n = 1; MIC 4 μg/
mL, n = 1; MIC 8 μg/mL, n = 3) 
compared with the MRSA reference 
strain ATCC 43300 (MIC 32 μg/mL). 
All isolates tested were susceptible 
to all non–β-lactam antibacterial 
agents, comprising glycopeptides, 
lipopeptides, fl uoroquinolones, macro-
lides, lincosamides, oxazolidinones, 
rifampins, streptogramins, glycyl-
cyclines, folate pathway inhibitors, 
aminoglycosides, and fosfomycin.
Until mecALGA251 is included as a 
diagnostic target in molecular MRSA 
detection tests, oxacillin/cefoxitin-
resistant isolates determined to be 
methicillin-susceptible by traditional, 
culture-based susceptibility testing 
methods should not be disregarded, 
even if mecA and/or PBP2a tests fail 
to detect their targets. Susceptibility 
patterns of mecALGA251-positive S. 
aureus isolates revealed low MICs 
of oxacillin compared with those for 
MRSA of the classical mecA type. 
We presume this indicates an altered 
affi nity of β-lactam antibacterial 
agents to the putative mecALGA251 gene 
product or a divergent expression of 
the gene. The choice and the dosage 
of antibacterial agents applicable 
for S. aureus infections should 
be reconsidered in light of this 
novel mecA homolog in molecular 
screening and identifi cation tests. 
Studies are warranted to investigate 
the prevalence of this novel MRSA 
entity in and outside of hospitals in the 
human population and in livestock, 
its clinical effects, and its response to 
antibacterial agent therapy.
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